Krystal Biotech Inc
NASDAQ:KRYS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
123.36
239.72
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
KRYS
stock under the Base Case scenario is
230.55
USD.
Compared to the current market price of 239.72 USD,
Krystal Biotech Inc
is
Overvalued by 4%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Krystal Biotech Inc.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Krystal Biotech Inc
Balance Sheet Decomposition
Krystal Biotech Inc
| Current Assets | 925.7m |
| Cash & Short-Term Investments | 731.1m |
| Receivables | 129.6m |
| Other Current Assets | 64.9m |
| Non-Current Assets | 314.4m |
| Long-Term Investments | 133.1m |
| PP&E | 156.3m |
| Other Non-Current Assets | 25m |
| Current Liabilities | 91.3m |
| Accounts Payable | 2.1m |
| Accrued Liabilities | 76.3m |
| Other Current Liabilities | 12.8m |
| Non-Current Liabilities | 11m |
| Other Non-Current Liabilities | 11m |
Free Cash Flow Analysis
Krystal Biotech Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Krystal Biotech Inc
|
Revenue
|
373.2m
USD
|
|
Cost of Revenue
|
-21.4m
USD
|
|
Gross Profit
|
351.8m
USD
|
|
Operating Expenses
|
-193.5m
USD
|
|
Operating Income
|
158.2m
USD
|
|
Other Expenses
|
40.7m
USD
|
|
Net Income
|
198.9m
USD
|
KRYS Profitability Score
Profitability Due Diligence
Krystal Biotech Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Score
Krystal Biotech Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
KRYS Solvency Score
Solvency Due Diligence
Krystal Biotech Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Krystal Biotech Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KRYS Price Targets Summary
Krystal Biotech Inc
According to Wall Street analysts, the average 1-year price target for
KRYS
is 226.9 USD
with a low forecast of 199.98 USD and a high forecast of 267.75 USD.
Dividends
Current shareholder yield for
KRYS is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
KRYS
stock under the Base Case scenario is
230.55
USD.
Compared to the current market price of 239.72 USD,
Krystal Biotech Inc
is
Overvalued by 4%.